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Background: Hepatitis C virus (HCV) infection involves changes not only from the point
of view of physical health, but also emotional, and social that have a significant impact on
the quality of life of these patients. According to the literature review, it seems that there is
an important association between psychosocial factors, in particular on a cognitive level
and disease progression. The aim of this mini-review is to summarize recent literature
looking at the associations between psychosocial and neurocognitive factors and HCV.
Methods: PubMed/Medline was systematically searched for psychosocial and
neurocognitive factors associated with hepatitis C, treatment adherence, and patient
wellbeing.
Results: Patients present with a range of extrahepatic symptoms including fatigue,
anxiety, depression, and neurocognitive dysfunction. HCV’s impact on quality of life and
wellbeing has serious clinical and social implications.
Conclusion: Hepatitis C and its management continue to have a profound impact on
health and psychologic wellbeing. Considering the serious extrahepatic implications
for individuals, it is imperative that healthcare professionals pay close attention to
psychosocial and neurocognitive factors. The focus on combined clinical approaches
could enhance understanding about the health and social impacts of hepatitis C along
the life course.
Keywords: hepatitis C, neurocognition, adherence, wellbeing, psychosocial factors
INTRODUCTION
The World Health Organization (WHO) estimates that about 3% of the world population (170
million people) is infected with the hepatitis C virus (HCV) (WHO, 1999). The disease’s potential
for evolution toward chronicity, hepatic cirrhosis, and hepatocellular carcinoma makes this the
main indicator for a liver transplant (Marinho and Barreira, 2013) before effective therapies arise.
Treatment for HCV changed in the last years from an interferon and ribavirin-based therapy to
being interferon-free. These are simpler oral regimens, shorter to administer with very high efficacy
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rates and better side effect profiles (Smith et al., 2015). However,
as advances in the treatment of HCV occur, it is imperative to
evaluate clinical outcomes, assessing and quantifying the efficacy
and impact of these regimens.
The identification of neuropsychiatric and neurocognitive
symptoms is important during and before treatment; however,
they still have little recognition or impact in clinical evaluation.
Further, these symptoms (depression, cognitive disorders) are
eventually associated to direct HCV neurotoxicity (Adinolfi et al.,
2015), negatively affecting the individual’s perceived Quality of
Life (QoL), daily functioning, work, and productivity. These
factors can lead to reduced involvement in medical care and life
projects as well as increased morbidity and mortality, decreasing
overall wellbeing, QoL, as well as treatment adherence (Younossi
et al., 2007; Schaefer et al., 2012; Adinolfi et al., 2015; Monaco
et al., 2015; Younossi and Henry, 2015; Chasser et al., 2017).
In a biopsychosocial model of the disease and the treatment,
it is essential to understand HCV’s clinical and social impact
on a broader life perspective and how individuals experience
it. The basic principles of this model, which uses a holistic
approach regarding illness, includes the biological, psychological,
and social dimensions of the person’s life and the perception that
the person suffers as a whole. The personality and the emotional
reserves of the patient as well as the particular environmental
conditions in which the person lives should be taken into
account (Papadimitriou, 2017). On the other hand, positive
psychology and focusing on wellbeing have inspired research
into the aspect of the relation between emotion and health;
namely, the relationship between subjective wellbeing and health
outcomes (Okely and Gale, 2015). Wellbeing, in the context of
a chronic condition such as HCV infection, must follow the
WHO’s inclusive definition of health and states of wellbeing
(Misselbrook, 2014). The literature explains this construct as
a combination of three different dimensions, each capturing a
different aspect: life evaluation (quality or goodness of ones’ life
and overall life satisfaction), hedonic wellbeing, and eudemonic
wellbeing. The hedonic dimension refers to the experience of
positive and negative affect (e.g., sadness or happiness) and
not to a unique positive affective valence, while the eudemonic
dimension captures meaning and purpose in life (Steptoe et al.,
2015). Thus, the aim of this article is to determine what is
currently known about neurocognitive and psychosocial factors
associated with HCV as well as to try to value disease adjustment
and the implications for health and wellbeing.
METHODS
The aim of this mini-review is to summarize the more recent
literature investigating the relationship between psychosocial and
neurocognitive factors associated with HCV and their impact on
patient wellbeing. We searched the Medline/PubMed databases.
No time period limits were placed, and the key terms included
“psychosocial,” “neurocognitive,” “hepatitis C,” and “wellbeing.”
In addition to this selection, some research gathered outside this




The chronic nature and individual experience of the disease
are conditioning factors on QoL, with clinical and social
implications, due not only to the diagnostic but also to its
evolution (Negro et al., 2015; Chasser et al., 2017; Iriana et al.,
2017). Several studies have stated that chronic hepatitis C may
lead to several complications anddespite the fact that most of the
patients with HCV are asymptomatic, they consistently report
a significant reduction in health-related QoL, when compared
with the general population (Baune and Air, 2016; Adinolfi et al.,
2017).
Psychosocial chronic stressors are well documented as
determinants of poor mental and physical health, leading to an
important burden in health systems, mortality, morbidity, and
psychological wellbeing, predominantly in developed societies
(Yarlott et al., 2017). The relationship between physical mental
and social health as well as the uncertainties about treatment and
HCV have been well documented, both in the past and in recent
literature (Hong et al., 2011; Kleinman et al., 2012; Armstrong
et al., 2016). Emotional distress and depressive disorders have
been reported in untreated HCV patients, pointing to a possible
role of the virus itself in their occurrence (Alavi et al., 2012;
El Khoury et al., 2012). Furthermore, studies suggest that a
deficiency of social relationships is a significant risk factor
for broad-based morbidity and mortality as well as negative
implications for health (Cacioppo and Cacioppo, 2014; Valtorta
et al., 2016). Whether these disorders are due to the uncertainty
of living with a chronic disease with potentially life-threatening
complications or to other psychosocial factors, remains under
discussion.
Another relevant factor is the stigma associated with HCV,
which may increase anxiety levels and the fear of transmitting
the virus. This fear may be the main cause for social isolation
and decreased intimacy in relationships (Younossi et al., 2007;
Armstrong et al., 2016). Stigma may be defined as a cluster
of attitudes expressed by a dominant group, which sees other
individuals’ behaviors as being socially unacceptable. The notion
of stigma, related to shameful relationships, and deviations
from what is considered to be the “norm,” has a long history
in the context of infectious diseases, as in the case of HCV
(Bogart et al., 2008). These norms, behaviors, and beliefs may
lead to alienation of family and social relationships as well as
(real or perceived) to discrimination at health settings or the
workplace.
Stigmatization affects not only patients but also health care
professionals who are not immune to stereotypes and judgments
that may influence treatment. These issues can promote an
increase in patients’ isolation, in therapeutic continuity, and a
decrease in the search for medical help (Butt, 2008). Furthermore,
several studies have suggested that stigma is associated with low
treatment adherence (Kamaradova et al., 2016), including in
HCV patients (Treloar et al., 2013). Implementing psychological
strategies and intervention models (e.g., psychoeducation;
information-motivation-behavioral skills) should be a major
concern.
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A recent systematic review has shown that non-adherence to
the HCV treatment regimen is associated with virologic response
failure (Lieveld et al., 2013), supporting that optimal adherence
is needed to achieve treatment success in this area (Mathes
et al., 2014). This also becomes a public health issue, since non-
adherence favors the development and spread of resistant HCV
mutations, highlighting adherence’s crucial role in treatment
success (Weiss et al., 2009).
Investigations about medication adherence indicate the need
to analyze interconnected factors related to the complexity of
therapeutic regimes (treatment of HCV and comorbidities),
relevance of side effects (nausea, pruritus, insomnia, diarrhea,
and asthenia) (Feld et al., 2014), but also patient-related
variables. Research points to a steady correlation between
individual characteristics, illness behaviors, health literacy, and
low adherence to treatment. Among sociodemographic and
clinical factors, gender, depression, psychiatric diagnosis in
general, illicit drug use, HIV co-infection, treatment regimen,
and hemoglobin level were identified as being significantly
and consistently associated with adherence/non-adherence. Age,
race, unemployment, being unmarried, genotype, treatment
experience, disease severity, and HCV-related costs were
classified as inconsistent predictors of non-adherence (Lieveld
et al., 2013; Mathes et al., 2014).
From a psychological point of view, factors such as
information, personal beliefs, personality traits, social context
and the way they interact toward health-promoting behaviors,
allow a better understanding of adherence bases, helping
to implement individualized adaptive strategies. Further, the
general physical symptomatology related to HCV can vary
from musculoskeletal discomfort to chronic fatigue (Armstrong
et al., 2016). In a recent study, Boscarino et al. (2015) reported
that poor physical health in patients with HCV was associated
with demographic factors, including income, health insurance
status, marital status, and also connected with stressful life
events, social support or having a liver transplant. Despite the
needed level of adherence (95% or higher), non-adherence should
not be a factor of exclusion to initiate antiviral treatment,
but rather a factor that induces a careful evaluation in the
stage of pre-prescription, as well as the implementation of
strategies designed to promote adherence in the context of
a multi-disciplinary team. Thus, we argue that an integrated
medical and psychological approach is fundamental, being
associated with a higher adherence and to a better therapeutic
response.
The following steps have proven to be crucial for the success
of the treatment: to evaluate the patient’s preparation to start
and adhere to the therapeutic regime, to choose a therapeutic
regime that may improve adherence, and to select and to apply
interventions during the therapeutic regime.
Hepatitis C virus diagnosis is reported by individuals
as having a profound impact on their social functioning
and wellbeing. Psychosocial factors (social support, coping
mechanisms) not only interfere in the way the subject
interprets and experiences symptoms, but they also influence
the medical treatment and modify behaviors (Bielski and Chan,
1976).
NEUROCOGNITION AND HEPATITIS C
The involvement of the central nervous system (CNS), found
in recent studies, supports a pathogenic role for HCV in
neuropsychiatric and neurocognitive disorders (Monaco et al.,
2015). In a recent review, Yarlott et al. (2017) called this
association between HCV, cognitive impairment, fatigue and
depression the “Hepatitis C Virus Brain Syndrome.” This
syndrome is probably generated by peripheral immune responses
affecting the CNS, neuroinflammation associated with CNS HCV
infection, as well as to negative life events and other psychogenic
stressors (Yarlott et al., 2017).
Forton et al. (2001) showed evidence that HCV can cross
the blood-brain barrier and replicate in the CNS, emerging
through infected monocytes and infecting microglial cells.
Using proton magnetic resonance spectroscopy in patients and
controls, they found an increase in basal ganglia and white
matter choline/creatine ratios in patients, suggesting an altered
metabolism in patients with chronic HCV; these results were
not explained by hepatic encephalopathy or history of drug use
(Forton et al., 2001).
Neurocognitive impairment, one of the most common
extrahepatic manifestations of HCV, can lead to subtle changes
in processing speed, memory, attention, fatigue, and cognitive
performance. Up to 50% of HCV-infected patients may develop
clinical or subclinical manifestations of this dysfunction, and
these cognitive deficits are independent of the stage of the liver
disease (Lowry et al., 2010; Ferri et al., 2016; Iriana et al., 2017).
Hilsabeck et al. (2002) found that HCV patients experience
cognitive deficits, especially in attention, learning, psychomotor
speed, and mental flexibility. This study shows that maintaining
attention and concentration while performing accurately was
the most difficult task for non-cirrhotic patients, with 50%
taking an abnormally long time to complete the task, 28.9%
making a significant number of omission errors, and about
20% of non-cirrhotic patients performing in the impaired range
involving attention/concentration, visual scanning and tracking,
psychomotor speed, and mental flexibility (Hilsabeck et al., 2002).
The authors suggest that this cognitive impairment is similar
to that reported in patients with a neurocognitive disorder
associated to other chronic illness, such as HIV and AIDS-
related dementia, and that these deficits affect QoL and functional
capacity in patients (Hilsabeck et al., 2002).
Regarding cognitive and psychiatric dysfunctions, several
studies were performed to assess the impact of HCV in patients,
namely depression, anxiety, fatigue, attention, executive function,
and visuospatial function deficits (Monaco et al., 2015; Thames
et al., 2015). Cognitive impairments were previously thought to
be associated with the development of hepatic encephalopathy
(Gaeta et al., 2013). However, their presence was demonstrated in
the absence of advanced liver disease as well as in the absence of
HIV co-infection, depression, or substance abuse (Cherner et al.,
2005; Kuhn et al., 2017; Yarlott et al., 2017). Despite the absence
of those comorbidities, deficits in attention, concentration,
psychomotor speed, and verbal fluency have been reported
in HCV patients (Weissenborn et al., 2004; Clifford et al.,
2009). Findings remain controversial and it is unclear if HCV
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eradication improves HCV-associated neurological compromise
(Kuhn et al., 2017). Bladowska et al. (2013) in a follow-up study
over 48 weeks after the cessation of treatment, found significant
improvement in attention and working memory in patients
who successfully cleared the virus. This finding suggests that
over time, the benefits of HCV clearance can be more marked.
However, in other research protocols sustained virologic response
(SVR) was not related to any improvement in neurocognitive
performance (Huckans et al., 2015; Lowry et al., 2016).
Therefore, the neurocognitive profile of these patients before
treatment needs to be addressed due to the possible implications
on the treatment course (e.g., non-adherence-like behavior due to
cognitive abnormalities). Additionally, it is important to address
other risk factors that can have a negative impact on cognition.
The high rate of substance abuse and the prevalence of psychiatric
disorders among HCV-infected patients are important factors
associated with cognitive impairment that trigger poor adherence
and treatment efficacy (Wiêdłocha et al., 2017).
Several studies have suggested that earlier treatment is
associated with improvement of the QoL in chronic HCV patients
(Marinho and Barreira, 2013; Boscarino et al., 2015; Lucaciu and
Dumitrascu, 2015; Negro et al., 2015; Chasser et al., 2017; Iriana
et al., 2017), highlighting the importance of HCV treatment. In
order to optimize treatment outcomes, a pretreatment profile
helps to identify risk factors that can be modifiable before and
during treatment, such as treatment disruption, non-adherence,
the risk of (re)infection and risk of emergence of depressive
disorders (Basseri et al., 2010).
The pre-vs.-post treatment neurocognitive changes that may
occur among SVR patients require further research to understand
the impact of neuroanatomical and functional changes in HCV
patients before, over the course of treatment, and after successful
clearance of the virus.
DISCUSSION AND CONCLUSION
This mini-review shows that patients with HCV often feel
stigmatized and unsupported in their care, relationships, and
work environments, while simultaneously coping with physical
and psychological symptoms. This synthesis points to areas where
greater education, compassion, and patient-centered healthcare
could improve the experience of people living with HCV.
In a broader perspective, and trying to close the loop,
neurocognitive impairment can be responsible for therapy
non-adherence in several diseases (Rohde et al., 2017; Smith
et al., 2017) and for losing internal resources to deal with a
chronic disease (Boehmer et al., 2016). Adaptive behavior is
therefore impaired, social networks are disrupted and patients’
deficits in instrumental daily life abilities are increased. These are
factors known to be associated to a worse QoL (Vilhena et al.,
2014), potential complications in disease evolution (Vere, 2009),
and overall a worse prognosis. Whether, mediating variables
in this process include individual psychological traits, negative
or positive affective states, cognitive impairment, biological
responses associated to more pathogenic viral stripes, or to the
combination of multiple disease-factors, is yet an open debate.
However, the relevance of those psychosocial variables in chronic
diseases is nowadays unquestionable (Fava et al., 2016; Kemp,
2017; McLachlan and Gale, 2018). In what concerns wellbeing, all
the described dimensions may be affected by psychosocial factors
and they can be managed through an integrated intervention.
Actions on preventing, identifying and treating hepatitis C should
be a priority and need to be included in local health and wellbeing
strategies in order to promote better health outcomes.
The association between neurocognitive functions,
psychological wellbeing, and activities of daily living among
patients with hepatitis C has had little attention. Understanding
factors, which can impact physical functioning and psychological
wellbeing, may have an important clinical relation to improving
outcomes for patients with this disease.
Treatment of HCV requires education efforts of a wide base,
with the goal of improving knowledge, and attitudes about this
disease. These efforts must include patients and their families,
policy decisions, health care professionals, and society as a whole.
A thorough study of HCV-associated stigma, clinical, and social
implications is essential for helping patients to cope with the
disease.
Investigation supports that HCV experience and treatment
adjustment may be facilitated through the use of theoretical
informed psychological interventions. Considering the impact
of HCV infection in patients’ mental health and wellbeing,
before, and during treatment, an interdisciplinary approach
should be followed and encouraged. Besides HCV-associated
depression, more studies are needed to characterize the eventual
neurocognitive side effects of the new interferon-free regimes and
their impact on mood comorbidities.
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